Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Notes Payables: 2012-2015

Historic Notes Payables for Ligand Pharmaceuticals (LGND) over the last 3 years, with Mar 2015 value amounting to $198.6 million.

  • Ligand Pharmaceuticals' Notes Payables rose 3341.97% to $198.6 million in Q1 2015 from the same period last year, while for Mar 2015 it was $198.6 million, marking a year-over-year increase of 3341.97%. This contributed to the annual value of $196.2 million for FY2014, which is 2054.37% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Notes Payables of $198.6 million as of Q1 2015, which was up 1.18% from $196.2 million recorded in Q4 2014.
  • Over the past 5 years, Ligand Pharmaceuticals' Notes Payables peaked at $198.6 million during Q1 2015, and registered a low of $1.4 million during Q1 2012.
  • Moreover, its 3-year median value for Notes Payables was $13.2 million (2013), whereas its average is $71.7 million.
  • In the last 5 years, Ligand Pharmaceuticals' Notes Payables plummeted by 80.16% in 2014 and then surged by 3,341.97% in 2015.
  • Quarterly analysis of 4 years shows Ligand Pharmaceuticals' Notes Payables stood at $14.8 million in 2012, then crashed by 38.60% to $9.1 million in 2013, then spiked by 2,054.37% to $196.2 million in 2014, then surged by 3,341.97% to $198.6 million in 2015.
  • Its Notes Payables was $198.6 million in Q1 2015, compared to $196.2 million in Q4 2014 and $194.0 million in Q3 2014.